Treatment of Waldenstrom's macroglobulinemia with thalidomide

Journal of Clinical Oncology

Volumn 19, Issue 16, 2001, Pages 3596-3601

  Dimopoulos, M A ^a   Zomas, A ^a   Viniou, N A ^a   Grigoraki, V ^a   Galani, E ^a   Matsouka, C ^a   Economou, O ^a   Anagnostopoulos, N ^a   Panayiotidis, P ^a  

^a NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; THALIDOMIDE;

ADULT; AFFECTIVE NEUROSIS; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FATIGUE; HEADACHE; HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0035881040     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.16.3596     Document Type: Article

References (22)

1. The spectrum of IgM monoclonal gammopathy in 430 cases
2. Waldenstrom's macroglobulinemia
3. Waldenstrom's macroglobulinemia: Clinical features, complications and management
4. Waldenstrom's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil
5. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia
6. Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity
7. Antitumor activity of thalidomide in refractory multiple myeloma
8. Reporting results of cancer treatment
9. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine
10. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
11. Thalidomide in patients with advanced multiple myeloma
12. Thalidomide for resistant and relapsing myeloma
13. Thalidomide in the treatment of relapsed multiple myeloma
14. Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma
15. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
16. Thalidomide: A revival story
17. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma
18. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma
19. A phase II trial of thalidomide in the treatment of relapsed multiple myeloma with laboratory correlative studies
20. Effect of thalidomide on myeloma cell apoptosis and VEGF secretion
21. Bone marrow angiogenesis in Waldenstrom's macroglobulinemia
22. Thalidomide in hematologic malignancies: Future directions